Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Equity Average (2022 - 2025)

Entrada Therapeutics has reported Equity Average over the past 4 years, most recently at $323.4 million for Q4 2025.

  • Quarterly results put Equity Average at $323.4 million for Q4 2025, down 24.0% from a year ago — trailing twelve months through Dec 2025 was $323.4 million (down 24.0% YoY), and the annual figure for FY2025 was $367.4 million, up 9.5%.
  • Equity Average for Q4 2025 was $323.4 million at Entrada Therapeutics, down from $360.1 million in the prior quarter.
  • Over the last five years, Equity Average for TRDA hit a ceiling of $426.2 million in Q3 2024 and a floor of $218.3 million in Q2 2023.
  • Median Equity Average over the past 4 years was $266.7 million (2022), compared with a mean of $307.1 million.
  • Biggest five-year swings in Equity Average: soared 87.92% in 2024 and later fell 24.0% in 2025.
  • Entrada Therapeutics' Equity Average stood at $222.9 million in 2022, then grew by 9.7% to $244.5 million in 2023, then soared by 74.05% to $425.6 million in 2024, then fell by 24.0% to $323.4 million in 2025.
  • The last three reported values for Equity Average were $323.4 million (Q4 2025), $360.1 million (Q3 2025), and $398.4 million (Q2 2025) per Business Quant data.